Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains

Diagnostic Microbiology and Infectious Disease

Volumn 79, Issue 4, 2014, Pages 438-440

  Citron, Diane M ^a   Tyrrell, Kerin L ^a   Goldstein, Ellie J C ^a,b  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dalbavancin; Osteomyelitis; Staphylococcus

Indexed keywords

COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; DOXYCYCLINE; LEVOFLOXACIN; LINEZOLID; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT; TEICOPLANIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; HETERORESISTANT VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS LUGDUNENSIS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OSTEOMYELITIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84904114236     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.05.014     Document Type: Article

References (13)

1. Acharya S., Soliman M., Egun A., Rajbhandari S.M. Conservative management of diabetic foot osteomyelitis. Diabetes Res Clin Pract 2013, 101:e18-e20.
2. Aslangul E., M'Bemba J., Caillat-Vigneron N., Coignard S., Larger E., Boitard C., et al. Diagnosing diabetic foot osteomyelitis in patients without signs of soft tissue infection by coupling hybrid 67Ga SPECT/CT with bedside percutaneous bone puncture. Diabetes Care 2013, 36:2203-2210.
3. Boucher H., Miller L.G., Razonable R.R. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2010, 51(Suppl. 2):S183-S197.
4. Chong Y.P., Park S.J., Kim H.S., Kim E.S., Kim M.N., Kim S.H., et al. In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC. Diagn Microbiol Infect Dis 2012, 73:264-266.
5. Citron D.M., Goldstein E.J., Merriam C.V., Lipsky B.A., Abramson M.A. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007, 45:2819-2828.
6. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Clinical and Laboratory Standards Institute document M7-A9 2012, CLSI, Wayne, Pa. 9th ed.
7. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24 2014, CLSI, Wayne, Pa.
8. Jones R.N., Flamm R.K., Sader H.S. Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn Microbiol Infect Dis 2013, 76:122-123.
9. Karlowsky J.A., Adam H.J., Poutanen S.M., Hoban D.J., Zhanel G.G., Canadian Antimicrobial Resistance A In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011, 69:342-347.
10. Salem A.H., Zhanel G.G., Ibrahim S.A., Noreddin A.M. A Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against ICU-isolated MRSA. Clin Exp Pharmacol Physiol 2014, 41(6):437-443.
11. Seaton R.A., Malizos K.N., Viale P., Gargalianos-Kakolyris P., Santantonio T., Petrelli E., et al. Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database. J Antimicrob Chemother 2013, 68:1642-1649.
12. Solon E.G., Dowell J.A., Lee J., King S.P., Damle B.D. Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits. Antimicrob Agents Chemother 2007, 51:3008-3010.
13. Taha A.B. Relationship and susceptibility profile of Staphylococcus aureus infection diabetic foot ulcers with Staphylococcus aureus nasal carriage. Foot (Edinb) 2013, 23:11-16.